PRIMA试验结果:在未活检人群中比较STHLM3检测与前列腺特异性抗原在全科医疗中检出前列腺癌的效果
PRIMA前瞻性研究在1905名50-69岁未活检男性中比较STHLM3检测与PSA作为MRI准入试验。STHLM3阳性(风险≥11%)较PSA≥3 ng/ml将GG≥2前列腺癌检出从30例增至37例(23.3%,95%CI 5.6-52.2%),但未改善特异性。STHLM3风险≥15%与PSA≥3 ng/ml的GG≥2检出无显著差异(30 vs 32;6.6%,95%CI -8.1%至25.9%),但减少MRI扫描(320降至236,-26.2%,95%CI -33.1%至-18.9%)。
要点
- STHLM3阳性(风险≥11%)较PSA≥3 ng/ml提高GG≥2前列腺癌检出(30例增至37例)。
- STHLM3风险≥15%与PSA≥3 ng/ml的GG≥2检出无显著差异(30 vs 32)。
- STHLM3风险≥15%较PSA≥3 ng/ml减少MRI扫描(320降至236)。
核心结论
- STHLM3阳性(风险≥11%)提高了GG≥2前列腺癌检出的敏感性但未提高特异性。
- 需进一步研究验证使用更高STHLM3阳性阈值作为MRI准入试验的可能获益。
研究设计与样本
- 前瞻性研究,纳入50-69岁未活检且在全科医疗接受PSA检测的男性。
- PSA 1-10 ng/ml者接受STHLM3检测,STHLM3阳性(风险≥11%)和/或PSA≥3 ng/ml者转诊MRI,PI-RADS评分≥3者接受靶向MRI引导活检。
- 2018年1月至2021年12月共招募1905名男性,其中1134名接受STHLM3检测。
主要发现
- 437名接受MRI,117名接受MRI引导活检,检出38例(32.5%)GG≥2和52例(44.4%)GG 1前列腺癌。
- STHLM3阳性(风险≥11%)较PSA≥3 ng/ml将GG≥2检出从30例增至37例(23.3%,95%CI 5.6-52.2%),GG 1检出从37例增至50例(35.1%,95%CI 11.6-66.7%)。
- STHLM3风险≥15%与PSA≥3 ng/ml的GG≥2检出无显著差异(30 vs 32;6.6%,95%CI -8.1%至25.9%),GG 1检出无显著差异(37 vs 37;0.0%,95%CI -19.6%至25.0%)。
- STHLM3风险≥15%与PSA≥3 ng/ml的MRI引导活检使用无显著差异(88 vs 83;-5.7%,95%CI -17.9%至7.4%),但MRI扫描从320降至236(-26.2%,95%CI -33.1%至-18.9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究验证使用更高STHLM3阳性阈值作为MRI准入试验的可能获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current management of prostate cancer (PC) lacks biomarker tests and diagnostic procedures that can accurately distinguish clinically significant and clinically insignificant PCs at an early stage of the disease. OBJECTIVE: To compare the Stockholm 3 (STHLM3) test and prostate-specific antigen (PSA) as entry tests for magnetic resonance imaging (MRI) in a prospective study of PC diagnosis in general practice. DESIGN, SETTING, AND PARTICIPANTS: Participants were biopsy-naïve men aged 50-69 yr who had a PSA test in general practice. Participants with PSA 1-10 ng/ml also had an STHLM3 test and were referred for MRI if the STHLM311 test was positive (risk ≥11%) and/or PSA ≥3 ng/ml, and to targeted MRI-guided biopsy (MRGB) if their Prostate Imaging-Reporting and Data System (PI-RADS) score was ≥3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the number of International Society of Urological Pathology grade group ≥2 (GG ≥2) cases detected with a positive STHLM311 test versus PSA ≥3 ng/ml. Post hoc analysis was performed using a higher STHLM3 test cutoff (risk ≥15%; positive STHLM315 test). RESULTS AND LIMITATIONS: Between January 2018 and December 2021, we recruited 1905 men. The STHLM3 test was performed in 1134 participants. Of these, 437 underwent MRI and 117 underwent MRGB, which detected 38 (32.5%) GG ≥2 and 52 (44.4%) with GG 1 cases. In comparison to PSA ≥3 ng/ml, a positive STHLM311 test increased detection of GG ≥2 from 30 to 37 cases (23.3%, 95% confidence interval [CI] 5.6-52.2%) and detection of GG 1 from 37 to 50 cases (35.1%, 95%CI 11.6-66.7%). STHLM315 positivity did not differ from PSA ≥3 ng/ml regarding detection of GG ≥2 PC (30 vs 32; 6.6%, 95% CI -8.1% to 25.9%), GG 1 PC (37 vs 37; 0.0%, 95% CI -19.6% to 25.0%), or MRGB use (88 vs 83; -5.7%, 95% CI -17.9% to 7.4%), but reduced MRI scans from 320 to 236 (-26.2%, 95% CI -33.1% to -18.9%). CONCLUSIONS: The STHLM311 test improved sensitivity but not specificity for detection of GG ≥2 PC in the clinical setting of nonsystematic PC testing in general practice. Further studies are needed to validate a possible benefit of using a higher cutoff for STHLM3 positivity as an entry test for MRI. PATIENT SUMMARY: We used a test called STHLM3 for detection of prostate cancer in general practice and compared its performance to the conventional PSA (prostate-specific antigen) test. We found that STHLM3 test results of 11% or above were not better at selecting men for MRI (magnetic resonance imaging) scans than the PSA test with a cutoff of 3 ng/ml or above. Analysis suggested that a higher cutoff for a positive STHLM3 test may improve selection of men for MRI scans, but further validation is needed.
引用
- Fredsøe J, Sandahl M, Vedsted P, et al. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population. Eur Urol Oncol. 2023. PMID: 37537016. doi:10.1016/j.euo.2023.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。